Results of a pharmacoeconomic analysis of the rationality of the use of acute myeloid leukemia chemotherapy regimens with the use of various doses of cytarabine
| Autor: | Natalia Bezuglaia, Iuliia Korzh, Oksana Tsurikova, Anastasiya Goncharova, Hanna Panfilova, Irina Zhirova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Environmental Engineering Physiology medicine.medical_treatment Microbiology Medical care Industrial and Manufacturing Engineering 03 medical and health sciences 0302 clinical medicine Internal medicine medicine QP1-981 Chemotherapy business.industry Myeloid leukemia Cancer medicine.disease Chemotherapy regimen QR1-502 030104 developmental biology QL1-991 Pharmacoeconomic Study 030220 oncology & carcinogenesis Cytarabine business Zoology Limited resources medicine.drug |
| Zdroj: | BIO Web of Conferences, Vol 30, p 03003 (2021) |
| ISSN: | 2117-4458 |
| DOI: | 10.1051/bioconf/20213003003 |
| Popis: | A pharmacoeconomic study of the rationality of the use of various chemotherapy regimens (“7 + 3” scheme) in the treatment of patients with acute forms of myeloid leukemia has been carried out. The use of the chemotherapy regimen “7 + 3” with 200 mg / m2 / per day dosage of cytarabine on 1-7 days allows to achieve a unit of treatment efficacy at a lower cost (CEA = 19.22 US $ / per unit of efficacy), compared with another dosage of cytarabine that was two times less, i.e., 100 mg / m² / day at the same period (CEA = US $ 20.18 / unit of effectiveness). The presented research results can be used in the formation of programs for the rational use of limited resources in the purchase of anticancer drugs for hematological cancer patients, as well as in the development of schemes for providing them with effective medical care in a hospital setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|